New hope for lung cancer patients: lorlatinib shows promise after other treatments fail
NCT ID NCT03909971
First seen Nov 05, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tested a drug called lorlatinib in 109 Chinese patients with advanced ALK-positive non-small cell lung cancer whose disease had worsened after previous ALK inhibitor treatment. The goal was to see how many patients' tumors shrank or disappeared. Results help doctors understand if lorlatinib can control the cancer when other drugs stop working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Chest Hospital, Capital Medical University
Beijing, 101149, China
-
Fifth Medical Center of PLA General Hospital
Beijing, 100071, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
Fujian Province Oncology Hospital
Fuzhou, Fujian, 350014, China
-
Gaoxin Hospital of The First Affilated Hospital of Anhui Medical University
Hefei, Anhui, 230088, China
-
General Hospital of Eastern Theater Command
Nanjing, China
-
Guangdong Provincial People's Hospital
Guangzhou, 510000, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hunan Provincial Tumor Hospital/Division of Oncology
Changsha, Hunan, 410013, China
-
Jilin Provincial Cancer Hospital
Changchun, Jilin, 130103, China
-
Shanghai Chest Hospital
Shanghai, 200030, China
-
Sichuan Province Cancer Hospital/Department of Pulmonary Tumor
Chengdu, Sichuan, 610041, China
-
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
Hangzhou, Zhejiang, 310016, China
-
Tangdu Hospital of Fourth Military Medical University
Xi’an, Shanxi, 710000, China
-
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, 310003, China
-
The Second Affiliated Hospital of Zhejiang University College of Medicine
Hangzhou, Zhejiang, 310009, China
-
The first hospital of jilin university
Changchun, Jilin, 130021, China
-
West China Hospital, Sichuan University, Cancer center
Chengdu, Sichuan, 610041, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhongshan Hospital, Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.